**阿斯利康与Absci达成2.47亿美元合作，共同研发抗癌药物**
英国《金融时报》周日报道，全球知名制药商阿斯利康与美国人工智能（AI）生物制药公司Absci达成了一项价值高达2.47亿美元的合作协议。双方将携手设计一种创新的抗癌抗体药物。
据悉，这次合作的核心目标是利用Absci先进的人工智能技术进行大规模的蛋白质分析。这种技术有望帮助科学家更快速、更准确地识别和定位潜在的肿瘤疗法。阿斯利康表示，这是他们长期研究和开发的重点方向，希望通过这种跨领域的合作，加速抗癌药物的研发进程。
随着科技的进步，AI技术在医学领域的应用越来越广泛。Absci公司的人工智能技术已经在多个领域得到了验证，其高效的数据分析能力为生物制药研究带来了革命性的变革。而阿斯利康作为全球领先的制药公司，其在肿瘤治疗领域的研究也一直处于行业前沿。
此次强强联手，不仅预示着两家公司在抗癌药物研发领域的深度合作，也为全球的癌症患者带来了新的希望。我们期待在不久的将来，能够看到这一合作带来的创新成果，为全球的抗癌斗争注入新的活力。
英语如下：
News Title: AstraZeneca Invests $247 Million in Joint Research withNews Title: AstraZeneca Invests $247 Million in Joint Research with AI Biopharmaceutical Giant Absci for New Anti-Cancer Drug
Keywords: AstraZeneca, Absci, Anti-cancer drug
News Content: **AstraZeneca and Absci Reach $247 Million Collaboration Agreement to Develop Anti-cancer Drug**
The Financial Times reported on Sunday that global pharmaceutical giant AstraZeneca has entered into a $247 million cooperation agreement with US artificial intelligence (AI) biopharmaceutical company Absci. The two companies will work together to design an innovative anti-cancer antibody drug.
According to reports, the core objective of this collaboration is to use Absci’s advanced AI technology for large-scale protein analysis. This technology is expected to help scientists identify and locate potential tumor therapies more quickly and accurately. AstraZeneca stated that this is a key focus of their long-term research and development efforts, and they hope to accelerate the development process of anti-cancer drugs through this cross-disciplinary collaboration.
With the advancement of technology, AI applications in the medical field are becoming increasingly widespread. Absci’s AI technology has been validated in multiple fields, and its efficient data analysis capabilities have brought revolutionary changes to biopharmaceutical research. AstraZeneca, as a leading global pharmaceutical company, has also been at the forefront of cancer treatment research.
This strong partnership not only indicates deep cooperation between the two companies in the field of anti-cancer drug research and development, but also brings new hope to cancer patients worldwide. We look forward to seeing the innovative results of this collaboration in the near future, injecting new vitality into the global fight against cancer.
【来源】https://www.ft.com/content/3d8a0ec6-5b04-486f-af2b-15de1486ffaf
Views: 1